详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.

107| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu [2]Departments of Nephrology,West China Hospital, Sichuan University, Chengdu [3]Departments of Neurosurgery,West China Hospital, Sichuan University, Chengdu [4]Laboratory of Cell and Molecular Biology, and State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China

出处：

DOI：

ISSN：

摘要：

SUMOylation, one of post-translational modifications, is covalently modified on lysine residues of a target protein through an enzymatic cascade reaction similar to protein ubiquitination. Along with identification of many SUMOylated proteins, protein SUMOylation has been proven to regulate multiple biologic activities including transcription, cell cycle, DNA repair, and innate immunity. The dysregulation of protein SUMOylation and deSUMOylation modification is linked with carcinogenesis and tumor progression. The SUMOylation-associated enzymes are usually elevated in various cancers, which function as cancer biomarkers to relate to poor outcomes for patients. Considering the significance of protein SUMOylation in regulating diverse biologic functions in cancer progression, numerous small-molecule inhibitors targeting protein SUMOylation pathway are developed as potentially clinical anticancer therapeutics. Here, we systematically summarize the latest progresses of associations of small ubiquitin-like modifier (SUMO) enzymes with cancers and small-molecular inhibitors against human cancers by targeting SUMOylation enzymes. We also compared the pros and cons of several special anticancer inhibitors targeting SUMO pathway. As more efforts are invested in this field, small-molecule inhibitors targeting the SUMOylation modification pathway are promising for development into novel anticancer drugs. Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2018]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q2 PHARMACOLOGY & PHARMACY

影响因子： 3.2 最新[2023版] 3.5 最新五年平均 3.853 出版当年[2018版] 3.777 出版当年五年平均 3.978 出版前一年[2017版] 3.664 出版后一年[2019版]

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu

通讯作者：

通讯机构： [1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu [*1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, No. 17, 3rd Section of People’s South Road, Chengdu, 610041, People’s Republic of China.

推荐引用方式(GB/T 7714)：

APA：

MLA：